| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6027714 | ASTRAZENECA | Formulation for inhalation |
Jan, 2018
(6 years ago) | |
| US6287540 | ASTRAZENECA | Formulation for inhalation |
Jan, 2018
(6 years ago) | |
| US7143764 | ASTRAZENECA | Inhalation device |
Mar, 2018
(6 years ago) | |
| US6142145 | ASTRAZENECA | Inhalation device |
May, 2018
(5 years ago) | |
Pulmicort Flexhaler is owned by Astrazeneca.
Pulmicort Flexhaler contains Budesonide.
Pulmicort Flexhaler has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Pulmicort Flexhaler are:
- US6027714
- US6287540
- US7143764
- US6142145
Pulmicort Flexhaler was authorised for market use on 12 July, 2006.
Pulmicort Flexhaler is available in powder, metered;inhalation dosage forms.
Pulmicort Flexhaler can be used as maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older, including patients requiring oral corticosteroid therapy for asthma.
The generics of Pulmicort Flexhaler are possible to be released after 08 May, 2018.
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 12 July, 2006
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older, including patients requiring oral corticosteroid therapy for asthma
Dosage: POWDER, METERED;INHALATION
PULMICORT FLEXHALER family patents
